Magnesium Bisglycinate for Health & Longevity

Evidence Review created on 11/07/2026 using AI4L + evidence-mcp / Opus 5.5

Also known as: Magnesium Glycinate, Magnesium Diglycinate, Magnesium Bis(glycinate), Magnesium Glycinate Chelate, Magnesium Bisglycinate Chelate

Motivation

Magnesium bisglycinate (magnesium glycinate) is a dietary supplement in which magnesium, a mineral that hundreds of the body’s enzymes depend on, is bound to two molecules of the amino acid glycine. It is sold as a gentle, well-absorbed form of magnesium, and many people take it to close the gap between the magnesium in their food and the amount the body needs.

Interest in this form grew from two sources: long-running population studies of magnesium intake and heart and metabolic health, and the form’s reputation for fewer digestive side effects than cheaper forms of magnesium. Supplement makers and health media now promote it mainly for sleep and relaxation, and placebo-controlled trials of this specific form remain few.

This review examines the evidence for and against magnesium bisglycinate as a health and longevity supplement: how it acts in the body, which claimed benefits rest on trials of this form and which on other forms of magnesium, its risks and drug interactions, and how it is dosed and monitored.

Benefits - Risks - Protocol - Conclusion

Expert commentary and practitioner content discussing magnesium bisglycinate, magnesium supplement forms or magnesium itself in depth.

No item from Peter Attia is listed: his magnesium-specific content, AMA #54 and other Ask Me Anything episodes on magnesium supplementation, is subscriber-only, with free pages giving only topic lists; his public episode #394 Sleep pharmacology covers magnesium only briefly within a broader supplement segment.

Grokipedia

  • Magnesium glycinate

    An AI-written encyclopedia entry with chemical identifiers (14.1% elemental magnesium), claimed uses and dosing; it treats glycinate and bisglycinate as one compound but overstates bioavailability claims relative to trial data.

Examine

  • Magnesium benefits, dosage, and side effects

    Examine has no page dedicated to bisglycinate; its primary magnesium page grades outcome-by-outcome trial evidence across all magnesium forms, useful for judging which effects are form-independent.

ConsumerLab

Systematic Reviews

No review is specific to bisglycinate; these systematic reviews and meta-analyses cover oral magnesium across forms, including its absorption, main claimed effects and adverse events.

Mechanism of Action

Magnesium is a cofactor for more than 600 enzymes. It binds ATP (adenosine triphosphate, the cell’s energy molecule) and is needed for DNA repair, protein synthesis and insulin signaling. In nerve and muscle it acts as a calcium antagonist (it competes with calcium): it blocks the NMDA receptor (a glutamate receptor that drives nerve excitation), enhances the GABA-A receptor (the brain’s main calming receptor), and relaxes vascular and airway smooth muscle, the proposed basis of its effects on sleep, mood, migraine and blood pressure.

In bisglycinate, one magnesium ion is chelated (bound at two points) by two glycine molecules; the compound is about 14% magnesium by weight, so 250 mg of magnesium carries about 1.5 g of glycine. One proposal is that part of the chelate is absorbed intact via a dipeptide pathway (carriers for two-amino-acid fragments) (Schuette 1994); this would bypass the TRPM6 channel (the gut and kidney magnesium channel) and leave less free magnesium to draw water into the bowel. A competing view holds that the chelate largely dissociates and absorbs like other soluble forms, so most effects reflect magnesium itself. Glycine, an inhibitory neurotransmitter, may add a sleep effect.

About 99% of body magnesium sits in bone, muscle and other cells, under 1% in serum. The kidneys hold serum levels in a narrow range and excrete the excess, so a dose has no simple half-life; action is non-selective, and there is no CYP-enzyme metabolism (the liver’s main drug-processing system). Glycine enters normal amino acid metabolism.

Historical Context & Evolution

Magnesium entered medicine as a laxative: Epsom salt (magnesium sulfate) was drawn from an English spring in the 1600s, and magnesium oxide and hydroxide became standard laxatives and antacids. Its essential role in nutrition was shown in animal feeding studies in the early 1930s, and clinical magnesium deficiency in people was characterized in the 1950s and 1960s, mainly in alcoholism, malabsorption and diuretic (urine-increasing drug) use.

Amino acid chelates were developed commercially from the 1960s onward, most prominently by Albion Laboratories in Utah, to make minerals more soluble and better tolerated. An isotope study in patients with surgically shortened bowels (Schuette 1994) supplied the main clinical rationale for the bisglycinate form: similar overall absorption to oxide, better absorption in the most impaired patients, and better tolerance.

Interest in magnesium for health optimization came from a meta-analysis of cohort studies linking higher intake to lower rates of diabetes, stroke and death (Fang 2016), and from meta-analyses of supplement trials on blood pressure (Zhang 2016) and glucose (Veronese 2021). Cohorts measured food intake; trials mostly used cheaper salts. Opinion has shifted in both directions: early enthusiasm for cramps faded after a Cochrane review found little benefit in older adults (Garrison 2020), while trials in people with low magnesium status renewed interest in targeted use. From the 2010s podcasters popularized bisglycinate for sleep, and the first placebo-controlled sleep trial of the form, using manufacturer-supplied product, appeared only in 2025 (Schuster 2025). Whether bisglycinate offers more than any well-absorbed magnesium salt remains open.

Expected Benefits

High 🟩 🟩 🟩

No benefit reaches High: each bisglycinate-specific clinical outcome rests on a single trial from one research group, and the replicated meta-analytic findings come from trials of other magnesium salts, which makes them indirect evidence.

Medium 🟩 🟩

Milder Insomnia Symptoms ⚠️ Conflicted

In a randomized controlled trial (RCT) of 155 adults reporting poor sleep, 250 mg elemental magnesium as bisglycinate nightly for four weeks lowered the Insomnia Severity Index (ISI, a validated 0–28 insomnia scale) more than placebo, without objective sleep measurement (Schuster 2025); Biogena made the product, and one author’s research firm is funded by supplement makers. A 2026 review of 12 RCTs across salts judged sleep evidence inconsistent and low-certainty (Lopresti 2026). Net: a small subjective benefit in poor sleepers, unconfirmed objectively.

Magnitude: ISI fell 1.6 points more than placebo over four weeks (95% CI, confidence interval, the range likely to contain the true value, 0.0 to 3.3; p = 0.049, where p is the probability of a difference this large arising by chance; Cohen’s d = 0.2, a standardized effect size where 0.2 is small) (Schuster 2025).

Better Lung Function in Magnesium-Deficient Asthma and Chronic Lung Disease

In a 12-month double-blind RCT of 224 adults with asthma or chronic obstructive pulmonary disease (COPD, a progressive airflow-limiting lung disease) and hypomagnesemia (serum magnesium below 1.6 mg/dL), 440 mg/day magnesium glycinate added to standard therapy improved FEV1 (forced expiratory volume in one second, the air exhaled in the first second) versus placebo (Maddirevula 2026). This is a single-center trial from one group in India, limited to magnesium-deficient patients, and is not yet replicated. The proposed mechanism is airway smooth-muscle relaxation.

Magnitude: FEV1 improved by 0.23 L in asthma and 0.19 L in COPD versus placebo (Maddirevula 2026).

Faster Depression Response When Added to Antidepressants

Magnesium’s NMDA-receptor blockade is shared with fast-acting antidepressants. In an open-label, nonrandomized trial of 44 patients on antidepressants, adding magnesium glycinate (112 mg elemental) for 28 days improved PHQ-9 (Patient Health Questionnaire-9, a validated depression scale) scores more than antidepressants alone (Siddique 2026). Absent blinding and randomization, and an unusually large effect, limit confidence. A meta-analysis of seven RCTs of various salts also found lower depression scores (Moabedi 2023). In a 90-patient glycinate RCT added to antidepressants, rising serum magnesium correlated with lower depression scores (Sultana 2025).

Magnitude: PHQ-9 scores improved 72.17% with added glycinate versus 26.42% with antidepressants alone at day 28 (between-group Cohen’s d = 1.76) (Siddique 2026).

Low 🟩

Lower Blood Pressure ⚠️ Conflicted

Magnesium relaxes vascular smooth muscle. A meta-analysis of 38 RCTs, mostly of other salts, found reductions concentrated in treated hypertension and hypomagnesemia (Argeros 2025); the TOHP trial of 360 mg/day bisglycinate in high-normal pressure found none (Yamamoto 1995). Net: benefit is limited to hypertension or deficiency.

Magnitude: Systolic −2.81 mm Hg (95% CI −4.32 to −1.29) and diastolic −2.05 mm Hg (95% CI −3.23 to −0.88) versus placebo (Argeros 2025); no significant change versus placebo with bisglycinate in high-normal blood pressure (Yamamoto 1995).

Better Blood Lipid Profile ⚠️ Conflicted

A meta-analysis of 78 RCTs of various salts found lower LDL and triglycerides and higher HDL (low- and high-density lipoprotein cholesterol) (Mohammadi 2026); an earlier meta-analysis found only higher HDL (Hariri 2025). No bisglycinate trial has measured lipids (indirect). Net: any lipid change is small and inconsistent.

Magnitude: LDL −3.21 mg/dL (95% CI −5.27 to −1.15), triglycerides −9.24 mg/dL (95% CI −16.87 to −1.61) and HDL +1.45 mg/dL (95% CI 0.37 to 2.54) versus control (Mohammadi 2026); Hariri 2025 found no LDL or triglyceride change.

Slightly Lower Body Weight ⚠️ Conflicted

A meta-analysis of 78 RCTs of various salts found a small weight reduction versus control (Mohammadi 2026); two earlier meta-analyses found no change (Askari 2021, Rafiee 2021). No bisglycinate trial has measured weight (indirect). Net: any weight effect is small and inconsistent.

Magnitude: Body weight −0.70 kg (95% CI −1.30 to −0.09) versus control (Mohammadi 2026); Askari 2021 and Rafiee 2021 found no significant change in body weight.

Better Glucose Control in or Near Diabetes ⚠️ Conflicted

A meta-analysis of double-blind RCTs, mostly of magnesium oxide, found lower fasting glucose in diabetes (Veronese 2021). A 12-week trial of glycinate plus vitamin D3 in overweight adults changed neither glucose nor insulin resistance (Dall 2023). Net: plausible in diabetes, untested for bisglycinate alone.

Magnitude: Fasting glucose standardized mean difference (SMD, effect size in standard-deviation units) −0.43 (95% CI −0.78 to −0.07) versus placebo in diabetes; HbA1c (three-month average blood glucose) unchanged (Veronese 2021).

Fewer Leg Cramps ⚠️ Conflicted

A bisglycinate RCT in 86 pregnant women reduced cramp frequency (Supakatisant 2015). A meta-analysis of four pregnancy RCTs found no effect (Liu 2021), and a Cochrane review found no meaningful benefit in older adults (Garrison 2020). Net: benefit is unlikely for age-related night cramps.

Magnitude: At least 50% fewer cramps in 86.0% versus 60.5% with placebo in pregnancy (Supakatisant 2015); in older adults −0.18 cramps per week (95% CI −0.84 to 0.49) versus placebo (Garrison 2020).

Lower Preeclampsia Risk in Pregnancy ⚠️ Conflicted

A meta-analysis of seven RCTs of various salts found fewer cases of preeclampsia (pregnancy-induced high blood pressure with organ strain) (Yuan 2022); an earlier Cochrane review found no significant reduction (Makrides 2014). No bisglycinate trial has tested it (indirect). Net: any reduction appears limited to high-risk pregnancies.

Magnitude: Preeclampsia relative risk (RR, risk relative to the comparison group) 0.76 (95% CI 0.59 to 0.98) versus control (Yuan 2022); RR 0.87 (95% CI 0.58 to 1.32) in the Cochrane review (Makrides 2014).

Migraine Prevention ⚠️ Conflicted

The American Academy of Neurology and American Headache Society (AAN–AHS), whose members derive no magnesium revenue, rated magnesium “probably effective” (AAN–AHS 2012 guideline). A meta-analysis of other salts found fewer attacks (Talandashti 2025); a 69-patient RCT found none (Pfaffenrath 1996). Net: a modest benefit, untested for bisglycinate (indirect).

Magnitude: 1.66 fewer monthly migraine days and 2.51 fewer attacks versus control (Talandashti 2025); responders 28.6% versus 29.4% with placebo (Pfaffenrath 1996).

Less Subjective Anxiety ⚠️ Conflicted

A systematic review found suggestive benefit in anxiety-prone groups but poor-quality trials of various salts (Boyle 2017). The bisglycinate sleep trial found no change in perceived stress or mood (Schuster 2025). Net: no reliable anxiety benefit is shown for bisglycinate.

Magnitude: Perceived Stress Scale 0.4 points difference versus placebo (95% CI −1.7 to 2.5; d = 0.04), not significant (Schuster 2025); Boyle 2017 reports no pooled figure.

Higher Hip Bone Density in Older Adults

In a meta-analysis of older-adult cohorts, higher magnesium intake was associated with higher hip bone mineral density (BMD, bone mass per area) (Groenendijk 2022). It found no fracture association, and no bisglycinate trial has measured bone outcomes; dietary intake differs from bisglycinate supplementation (indirect).

Magnitude: Pooled regression coefficient (β, the modeled change in hip BMD with intake) 0.03 (95% CI 0.01 to 0.06) (Groenendijk 2022).

Lower All-Cause Mortality ⚠️ Conflicted

A meta-analysis of cohorts totaling over one million people linked more dietary magnesium to lower mortality (Fang 2016). A later meta-analysis confirmed this for dietary magnesium but found no association for supplemental magnesium (Bagheri 2021). Net: a mortality benefit from supplements is not shown.

Magnitude: RR 0.90 (95% CI 0.81 to 0.99) per 100 mg/day more dietary magnesium (Fang 2016); no significant association for supplemental intake (Bagheri 2021).

Lower Risk of Type 2 Diabetes, Stroke and Heart Failure

In a meta-analysis of cohorts totaling over one million people, each additional 100 mg/day of dietary magnesium was associated with lower type 2 diabetes, stroke and heart failure incidence (Fang 2016). No supplement trial has tested incidence, and dietary intake differs from bisglycinate supplementation (indirect).

Magnitude: Type 2 diabetes RR 0.81 (95% CI 0.77 to 0.86), stroke RR 0.93 (95% CI 0.89 to 0.97) and heart failure RR 0.78 (95% CI 0.69 to 0.89) per 100 mg/day more dietary magnesium (Fang 2016).

Lower Colorectal Cancer Risk

In a meta-analysis of 14 cohorts, the highest dietary magnesium intake was linked to lower colorectal cancer incidence than the lowest (Meng 2019); an earlier meta-analysis of eight cohorts found a borderline association (Chen 2012). No supplement trial has tested incidence, and dietary intake differs from bisglycinate supplementation (indirect).

Magnitude: Colorectal cancer hazard ratio (HR, the relative rate of new cases over time) 0.80 (95% CI 0.73 to 0.87), highest versus lowest dietary intake (Meng 2019); RR 0.89 (95% CI 0.79 to 1.00) (Chen 2012).

Magnesium Repletion When Absorption Is Impaired

In a crossover RCT (each patient took both forms) of 12 patients after ileal resection (removal of the final small-intestine segment), labeled bisglycinate was absorbed as well as oxide overall, better in the most impaired, and better tolerated (Schuette 1994). A case report describes similar success (Tran 2026).

Magnitude: Absorption 23.5% versus 11.8% for oxide in the four most impaired patients, and 23.5% versus 22.8% overall (Schuette 1994).

Constipation Relief

Unabsorbed magnesium retains water in the bowel, softening stool. A systematic review rated magnesium salts moderately supported for chronic constipation (Rao 2021), including a 1.5 g/day magnesium oxide RCT (Morishita 2021). Bisglycinate is better absorbed and sold as less laxative, so the effect transfers poorly (indirect).

Magnitude: Overall symptom response 68.3% with magnesium oxide versus 11.7% with placebo over 28 days (Morishita 2021).

Less Muscle Soreness After Exercise

A systematic review of four trials in physically active adults found less soreness and fewer muscle-damage markers with magnesium (Tarsitano 2024). In its only glycinate trial, 22 students taking 350 mg/day for 10 days reported less soreness after strenuous bench pressing (Reno 2022); soreness was compared only within groups.

Magnitude: Soreness ratings fell about 1–2 points on a 0–6 scale from baseline with magnesium; the placebo group showed no significant change, for which the source gives no figure; not compared between groups (Reno 2022).

Speculative 🟨

Slower Biological Aging

A review links magnesium to every hallmark of aging (Dominguez 2024), and dietary magnesium extended lifespan in mice with progeria (a premature-aging disease) (Villa-Bellosta 2020). The basis is mechanistic and animal only.

Lower C-Reactive Protein ⚠️ Conflicted

C-reactive protein (CRP, an inflammation marker unvalidated against outcomes) fell with various salts (Veronese 2022) and glycinate in lung disease (Maddirevula 2026), not with glycinate plus vitamin D3 (Cheung 2022). Net: unconfirmed in healthy adults.

Better Endothelial Function ⚠️ Conflicted

Flow-mediated dilation (FMD, artery widening with blood flow), an unvalidated marker, rose in one meta-analysis of other salts (Darooghegi Mofrad 2018) but not another (Marques 2020). Net: unconfirmed, and untested for bisglycinate.

Lower Liver Enzymes ⚠️ Conflicted

ALT and AST (alanine and aspartate aminotransferase, liver-cell enzymes), unvalidated markers, fell in a seven-trial meta-analysis (Leyva-Velázquez 2026) but not in a 78-trial one (Mohammadi 2026). Net: unconfirmed, and untested for bisglycinate.

Benefit-Modifying Factors

  • Baseline magnesium status: Benefits concentrate in people with low intake or hypomagnesemia: in a meta-analysis, blood pressure fell more with hypomagnesemia or treated hypertension than overall (Argeros 2025), and exploratory analyses suggested greater insomnia improvement with low self-reported dietary intake (Schuster 2025).
  • Genetic polymorphisms: Two protein-altering TRPM6 variants suggestively raised diabetes risk only in women with low magnesium intake (Song 2009); a whole-genome scan pooling several cohorts linked TRPM6 variants, among six gene regions, to serum levels (Meyer 2010).
  • Sex: The Institute of Medicine (IOM), whose panel members derive no revenue from magnesium sales, sets allowances of 420 mg/day for men and 320 mg/day for women (IOM Dietary Reference Intakes). The bisglycinate sleep trial enrolled 80% women (Schuster 2025); no sex-specific efficacy analysis exists.
  • Pre-existing conditions: Treated hypertension, type 2 diabetes, malabsorption (bowel resection, bariatric surgery) and deficiency-associated lung disease show the clearest responses; well-nourished people with normal blood pressure show little effect on it.
  • Age: Older adults absorb less and are more often deficient; a meta-analysis in older adults found faster sleep onset (Mah 2021), and a muscle meta-analysis suggested benefit in the elderly but not athletes (Wang 2017).
  • Magnesium-depleting medications: Long-term proton pump inhibitors (PPIs, acid-suppressing drugs such as omeprazole) and metformin are associated with low plasma magnesium (van Orten-Luiten 2019), raising the likelihood of benefit.

Potential Risks & Side Effects

High 🟥 🟥 🟥

No risk reaches High: no bisglycinate trial has documented an excess of any adverse event over placebo, and the serious harms on record come from case series of other magnesium salts.

Medium 🟥 🟥

No risk reaches Medium: the two bisglycinate RCTs (Schuster 2025, Supakatisant 2015) found no excess adverse events, and evidence of harm rests on case reports or on trials of other magnesium salts.

Low 🟥

Gastrointestinal Upset and Loose Stools ⚠️ Conflicted

Unabsorbed magnesium draws water into the bowel. A Cochrane review across salts found a non-significant excess of minor, mostly gastrointestinal, adverse events with magnesium (Garrison 2020); bisglycinate RCTs found no excess (Schuster 2025, Supakatisant 2015). Net: at 250–300 mg, bisglycinate causes no more upset than placebo.

Magnitude: Gastrointestinal events in 0 of 77 versus 3 of 76 with placebo (Schuster 2025); across salts, minor adverse events RR 1.51 (95% CI 0.98 to 2.33), affecting 11–37% versus 10–14% of controls (Garrison 2020).

Hypermagnesemia With Impaired Kidney Function

The kidneys excrete excess magnesium; when they fail, hypermagnesemia (abnormally high blood magnesium) can cause low blood pressure, weakness and slowed heartbeat. A case series described four symptomatic elderly patients with kidney dysfunction taking magnesium oxide, one fatal (Yamaguchi 2019). No bisglycinate cases are reported (indirect).

Magnitude: Four symptomatic cases, one death, all over 65 with renal dysfunction (case series, no control group).

Speculative 🟨

Oxalate Formation From Supplemental Glycine

Glycine can be converted to glyoxylate and then oxalate, the main component of most kidney stones; this matters in primary hyperoxaluria (inherited oxalate overproduction). The basis is mechanistic only.

Risk-Modifying Factors

  • Kidney function: Falling eGFR (estimated glomerular filtration rate, a measure of kidney filtering capacity) reduces magnesium excretion and is the main driver of hypermagnesemia (Yamaguchi 2019).
  • Genetic polymorphisms: No variant is known to raise magnesium toxicity. Variants in AGXT (gene for the liver enzyme that detoxifies glyoxylate) cause primary hyperoxaluria and would, by mechanism, raise oxalate from glycine.
  • Baseline biomarkers: Serum magnesium already near the upper reference limit (0.95 mmol/L; Costello 2016) leaves little margin before hypermagnesemia.
  • Sex: No sex-specific adverse-event data exist; pregnant women tolerated 300 mg/day of bisglycinate chelate without excess nausea or diarrhea (Supakatisant 2015).
  • Pre-existing conditions: Constipation or bowel dysmotility (slowed gut transit) increases magnesium absorption time; myasthenia gravis (autoimmune muscle weakness) and heart conduction block (slowed electrical signaling through the heart) are, by mechanism, sensitive to magnesium’s nerve-muscle and cardiac effects.
  • Age: Every hypermagnesemia case in the series was over 65, with kidney dysfunction and difficulty reporting symptoms (Yamaguchi 2019).
  • Concurrent magnesium sources: Magnesium laxatives, antacids, multivitamins and electrolyte powders add to the bisglycinate dose and raise total intake.

Key Interactions & Contraindications

Documented interactions:

  • Fluoroquinolone antibiotics (ciprofloxacin, levofloxacin): Magnesium-aluminum antacid within 4 hours before ciprofloxacin cut its bioavailability to 15–70% of control, risking treatment failure (Nix 1989); dosing the antibiotic 2 hours before or 6 hours after magnesium avoided it (Nix 1989).
  • Tetracycline antibiotics (doxycycline, minocycline): Aluminum-magnesium antacid reduced doxycycline exposure from 38.6 to 6.0 mg·h/L, to subtherapeutic levels (Deppermann 1989). Separating doses by several hours is the usual mitigation.
  • Bisphosphonates (bone-preserving osteoporosis drugs such as alendronate, risedronate): Supplements of multivalent cations (minerals such as calcium, iron and magnesium) interfere with alendronate absorption, reducing efficacy (FOSAMAX label); the label requires at least 30 minutes before other oral intake.
  • Integrase inhibitors (antiviral drugs for HIV, human immunodeficiency virus, such as dolutegravir): Polyvalent cations such as magnesium lower dolutegravir levels, risking loss of viral control (TIVICAY label); the label specifies dolutegravir 2 hours before or 6 hours after.
  • Levothyroxine: Co-administered magnesium aspartate reduced thyroxine exposure by 12%, magnesium citrate by 7% (not significant) (Attinger 2025), risking under-replacement. Separation by about 4 hours is common practice.
  • Gabapentin: Magnesium oxide 1 g reduced gabapentin exposure by 43% (Yagi 2012), risking weaker pain or seizure control. Gabapentin is usually taken at least 2 hours after magnesium.
  • Rosuvastatin (a cholesterol-lowering statin): Aluminum-magnesium hydroxide antacid lowered rosuvastatin exposure by 50%, risking weaker cholesterol lowering (CRESTOR label); the label specifies rosuvastatin at least 2 hours before the antacid.
  • Proton pump inhibitors (omeprazole, pantoprazole) and metformin: Associated with hypomagnesemia (PPIs adjusted odds ratio 1.71, odds ratio being relative odds of the outcome, in a meta-analysis; Srinutta 2019; metformin, van Orten-Luiten 2019), increasing magnesium need. Periodic serum magnesium checks track this.
  • Antihypertensives (blood-pressure-lowering drugs such as amlodipine; ACE inhibitors such as lisinopril, which block a vessel-tightening hormone): In a meta-analysis, systolic pressure fell 7.68 mm Hg in treated hypertensives (Argeros 2025), an additive lowering; home monitoring detects hypotension (low blood pressure).
  • Vitamin D3 supplements: Glycinate plus vitamin D3 raised 25-hydroxyvitamin D (the circulating vitamin D marker) the most of three trial arms (Cheung 2022), a favorable interaction; a repeat vitamin D level shows the combined effect.
  • Calcium supplements: Use was associated with hypomagnesemia in geriatric outpatients under 80 (van Orten-Luiten 2019), lowering magnesium status. Taking large calcium doses at a different time from magnesium is common practice.
  • Neuromuscular blockers (muscle-relaxing anesthesia drugs such as rocuronium): Magnesium salts may enhance and prolong neuromuscular blockade (rocuronium label); the label concerns intravenous magnesium, and oral supplements are unstudied. Disclosing supplement use before anesthesia mitigates it.
  • Other magnesium-containing products (magnesium laxatives, antacids, multivitamins, electrolyte powders): Their magnesium adds to the bisglycinate dose; magnesium oxide laxatives caused symptomatic, once fatal, hypermagnesemia in older patients with kidney dysfunction (Yamaguchi 2019). Counting all sources mitigates it.

Theoretical interactions (inferred from mechanism, not studied in humans):

  • Sedative-hypnotics (sleep-inducing drugs such as zolpidem), benzodiazepines (sedatives such as lorazepam) and alcohol: Inferred from additive GABA-A receptor enhancement; possible added drowsiness. Assessing individual response before driving mitigates it.
  • Potassium-sparing diuretics (urine-increasing drugs that retain potassium, such as amiloride, spironolactone): Inferred from reduced renal magnesium excretion; possible magnesium accumulation, especially with kidney impairment. A serum magnesium check after starting mitigates it.
  • Aminoglycosides (injectable antibiotics such as gentamicin): Inferred from magnesium’s inhibition of acetylcholine release at nerve-muscle junctions; possible prolonged weakness. Disclosing supplement use before treatment mitigates it.
  • Blood-pressure-lowering supplements (potassium, beetroot nitrate): Inferred from additive vasodilation; possible lightheadedness. Home blood pressure monitoring mitigates it.

Populations who should avoid Magnesium Bisglycinate:

  • Advanced chronic kidney disease or dialysis: KDIGO (Kidney Disease: Improving Global Outcomes) G4–G5, eGFR below 30 mL/min/1.73 m² (KDIGO 2024 guideline); its authors derive no magnesium revenue. Human harm: symptomatic, once fatal, hypermagnesemia in elderly renal-dysfunction patients taking magnesium oxide (Yamaguchi 2019); eGFR threshold unstated.
  • Existing hypermagnesemia (serum magnesium above 0.95 mmol/L, the upper reference limit; Costello 2016): Inferred from additive magnesium load; no human data on supplementation in this state.
  • Myasthenia gravis: Inferred from magnesium’s inhibition of acetylcholine release at the nerve-muscle junction; no human data with oral bisglycinate.
  • Primary hyperoxaluria: Inferred from glycine-to-oxalate conversion; no human data.

Risk Mitigation Strategies

Doses and timings below follow common practice unless cited.

  • Staying under the upper limit: Supplemental elemental magnesium at or below 350 mg/day (IOM Dietary Reference Intakes; IOM panelists derive no revenue from magnesium sales), unless supervised, limits diarrhea and cumulative overload.
  • Counting elemental magnesium: An 893 mg bisglycinate capsule supplies 125 mg magnesium (Schuster 2025); dosing by compound weight instead of elemental content causes under- or overdosing.
  • Checking kidney function first: An eGFR before starting and yearly, with no supplementation in advanced kidney disease, prevents hypermagnesemia.
  • Spacing interacting drugs: Dolutegravir 2 hours before or 6 hours after magnesium (TIVICAY label) and 30 minutes after alendronate (FOSAMAX label) prevent loss of drug efficacy.
  • Splitting and taking with food: Dividing doses above 200 mg and taking them with meals reduces gastrointestinal upset and loose stools.
  • Stop thresholds: Stopping and seeking medical advice when serum magnesium exceeds 0.95 mmol/L, the upper reference limit (Costello 2016), or when nausea, flushing, weakness or slow pulse appear limits hypermagnesemia.
  • Blood pressure checks on antihypertensives: Home readings for the first 2–4 weeks detect additive hypotension.
  • Verified chelates: Third-party-tested, non-buffered bisglycinate avoids hidden magnesium oxide that causes gastrointestinal effects.

Therapeutic Protocol

Timing, splitting, cycling and titration steps below reflect common practice unless cited.

  • Sleep-trial regimen: 250 mg elemental magnesium as bisglycinate (with about 1.5 g glycine) daily, taken 30–60 minutes before bed, for four weeks (Schuster 2025).
  • Practitioner sleep protocol: 200 mg magnesium bisglycinate 30–60 minutes before bed, popularized by Andrew Huberman (Huberman Lab newsletter); the source does not state whether 200 mg is elemental.
  • Repletion-focused intake: Official adult allowance 320–420 mg/day total and 350 mg/day supplemental upper limit (IOM Dietary Reference Intakes; IOM panelists derive no revenue from magnesium sales); Chris Kresser proposes 520–655 mg/day total from food plus bisglycinate (Chris Kresser article).
  • Disease-specific trial regimens: 300 mg/day bisglycinate chelate for pregnancy leg cramps (Supakatisant 2015); 440 mg/day glycinate for 12 months in hypomagnesemic asthma or COPD (Maddirevula 2026).
  • Best time of day: Evening for sleep goals; otherwise with meals for tolerance, and always separated from interacting drugs.
  • Half-life: Serum magnesium is held in a narrow range by the kidneys, so a dose has no simple half-life; chelate absorption peaked about 3 hours earlier than oxide (Schuette 1994), while tissue stores refill over weeks.
  • Single or split dose: Rhonda Patrick favors divided smaller doses for absorption (FoundMyFitness episode); the sleep trial used one nightly dose. Splitting suits doses above 200 mg.
  • Genetic polymorphisms: TRPM6 variants may alter magnesium handling (Song 2009), but no genotype-guided dosing exists.
  • Sex: Women’s allowance is about 100 mg/day lower than men’s (IOM Dietary Reference Intakes; IOM panelists derive no revenue from magnesium sales); no sex-specific bisglycinate dosing has been tested.
  • Age: Older adults, with lower absorption and kidney reserve, typically start at the low end of trial doses after an eGFR check.
  • Baseline biomarkers: Low intake or serum magnesium below 0.75 mmol/L, the lower reference limit (Costello 2016), marks a group with larger reported effects (Argeros 2025); values near the upper limit argue against supplementation.
  • Pre-existing conditions: In malabsorption, high-dose glycinate has been used under medical supervision (Tran 2026); in kidney disease, reduced excretion turns standard doses into a hypermagnesemia risk (Yamaguchi 2019).

Discontinuation & Cycling

  • Duration: Use is open-ended while a dietary shortfall persists; trials ran from four weeks (Schuster 2025) to 12 months (Maddirevula 2026).
  • Withdrawal effects: None reported; stopping returns magnesium status toward its dietary baseline over weeks.
  • Tapering: Not required; supplementation can stop at once.
  • Cycling: No evidence that cycling maintains efficacy, and no trial used it; magnesium is a nutrient without known tolerance.
  • Reassessment: Diet improvement, new kidney findings or new interacting drugs warrant re-evaluating the need or dose.

Sourcing and Quality

  • True chelate versus buffered blend: “Buffered” products mix bisglycinate with magnesium oxide to raise magnesium per capsule; ConsumerLab notes that chelates are bulky, needing larger capsules (ConsumerLab review). “Fully reacted” or “non-buffered” bisglycinate chelate on the label signals the pure form.
  • Elemental content: Pure bisglycinate is about 14% magnesium; labels are required to state elemental magnesium per serving (21 CFR 101.36; ConsumerLab review), and compound weight alone overstates the dose.
  • Third-party testing: USP Verified (United States Pharmacopeia), NSF Certified for Sport or ConsumerLab approval confirms content and screens for heavy metals and contaminants.
  • Raw material and brands: Albion’s TRAACS bisglycinate chelate is used by many brands; widely sold products include Doctor’s Best, Thorne, Pure Encapsulations and Life Extension (105 mg per capsule), presented without endorsement.
  • Glycine load: Each 100 mg of elemental magnesium carries about 0.6 g glycine, relevant only for people restricting glycine.

Practical Considerations

  • Time to effect: The sleep trial found the between-group insomnia difference at four weeks, with both groups improving within the first two weeks (Schuster 2025); a meta-analysis found blood pressure effects need about one month (Zhang 2016); repleting tissue stores takes weeks to months.
  • Common pitfalls: Confusing compound weight with elemental magnesium, buying buffered blends, taking magnesium alongside interacting drugs, combining several magnesium products, and expecting effects when magnesium status is already adequate.
  • Regulatory status: In the United States bisglycinate is sold as a dietary supplement; the FDA (Food and Drug Administration) has no authority to approve dietary supplements before they are marketed (FDA dietary supplements Q&A).
  • Cost and accessibility: Inexpensive and widely available; cost is not a barrier.
  • Research funding: As an unpatentable, low-cost nutrient, bisglycinate attracts little pharmaceutical or payer-funded research; form-specific trials are small and often use manufacturer-supplied product, a potential source of bias.

Interaction with Foundational Habits

  • Sleep: Direction: potentiating, modestly. Magnesium’s GABA-A enhancement and glycine’s inhibitory action may ease sleep onset; the bisglycinate trial dosed 30–60 minutes before bed (Schuster 2025). It does not replace light, timing and caffeine habits.
  • Nutrition: Direction: indirect. Food sources (pumpkin seeds, leafy greens, nuts, legumes) come first. Phytates (plant compounds that bind minerals) in grains and legumes reduce magnesium absorption (FoundMyFitness episode), as does high-dose zinc (FoundMyFitness episode); alcohol increases urinary loss (FoundMyFitness episode). Taking bisglycinate with meals improves tolerance.
  • Exercise: Direction: indirect. Sweat and training raise magnesium needs by at least 10–20% (FoundMyFitness episode); a meta-analysis found supplementation did not improve strength in athletes (Wang 2017). No blunting of training adaptation is reported; evening dosing after workouts is common.
  • Stress management: Direction: none shown for bisglycinate. Stress hormones are proposed to increase magnesium loss, but the bisglycinate trial found no change in perceived stress (Schuster 2025); breathing, exercise and sleep remain the primary tools.

Monitoring Protocol & Defining Success

Before starting, a baseline panel establishes kidney function and magnesium status: serum magnesium, serum creatinine with eGFR, and seated home blood pressure averaged over several days. These values identify people for whom supplementation carries the most risk (advanced kidney disease, high serum magnesium) and those most likely to benefit (low magnesium, raised blood pressure). A baseline Insomnia Severity Index is useful when sleep is the goal.

Ongoing monitoring follows this cadence: serum magnesium and eGFR at 8–12 weeks, then every 6–12 months; home blood pressure weekly for the first month in people taking antihypertensives, then monthly; the Insomnia Severity Index again at 4 weeks. Earlier testing is warranted after a dose increase, a new interacting drug, or symptoms of excess such as nausea, flushing or weakness. Success means a stable serum magnesium within range and improvement in the targeted marker.

Biomarker Optimal Functional Range Why Measure It? Context/Notes
Serum magnesium 0.75–0.95 mmol/L (standard reference range) Safety check (high values stop use) and marker expected to rise Under 1% of body magnesium is in serum, so normal values can coexist with low stores; the interval comes from 1970s population data, not outcomes (Costello 2016). Hemolysis (red cells broken during the blood draw) falsely raises the value; fasting is not required.
eGFR (from serum creatinine) No established target; track change from own baseline Safety check: declining values reduce or stop use KDIGO classes eGFR below 60 mL/min/1.73 m² as decreased kidney function (KDIGO 2024 guideline); its clinician authors derive no revenue from magnesium sales. Urine albumin is the usual paired test; heavy exercise or large meat meals the day before can raise creatinine.
Blood pressure (home, seated) Below 130/80 mm Hg treatment target (ACC–AHA 2025 guideline) Marker expected to fall; safety check on antihypertensives ACC–AHA: American College of Cardiology and American Heart Association. Normal blood pressure is below 120/80 mm Hg (ACC–AHA 2025 guideline); the guideline’s cardiology and primary-care society members derive no revenue from magnesium sales. Readings are typically taken morning and evening after 5 minutes’ rest, before medication.

Qualitative markers:

  • Sleep onset and quality: Time to fall asleep, night wakings and morning restedness, ideally with the Insomnia Severity Index.
  • Bowel habit: Stool consistency; loose stools signal excess dose or a buffered product.
  • Muscle cramps and twitching: Frequency of night cramps or eyelid twitches.
  • Headache days: Monthly migraine or headache days for those with migraine.
  • Mood and calm: Day-to-day irritability, low mood and sense of calm.

Emerging Research

  • Bisglycinate add-on in major depression (NCT07633080): Double-blind RCT, 84 patients, 220 mg magnesium plus 1,350 mg glycine daily for 8 weeks; primary outcome MADRS (Montgomery–Åsberg Depression Rating Scale); recruiting, completion 2028. A positive result would strengthen the depression item; a null result would weaken it.
  • Glycinate for elevated systolic pressure (NCT05690464): 120 adults, 480 mg/day glycinate versus placebo for 12 weeks; active, not recruiting, completion December 2026. A positive result would give direct form-specific blood pressure evidence; a null result would suggest the meta-analytic effect does not transfer.
  • Glycinate in untreated high blood pressure (NCT03688503): 59 adults, 480 mg/day for 12 weeks, office and 24-hour ambulatory pressure; completed August 2025, no results posted. Positive results would raise the blood pressure grade; null results would lower confidence.
  • Glycinate versus threonate in athletes (NCT07640685): 150 collegiate athletes, glycinate (240 mg elemental magnesium), magnesium L-threonate (156 mg) or placebo nightly for 28 days; primary outcome wearable-measured sleep efficiency; recruiting, completion June 2027. A positive result would add objective sleep data; a null result would weaken the sleep item.
  • Glycinate versus melatonin for insomnia (NCT06996171): 60 young adults, Insomnia Severity Index primary outcome; registered completion October 2025 has passed, the record still lists recruiting, and no results are posted. A positive result would support the insomnia item; a null result would weaken it.
  • Earlier glycinate trials: Hot flashes, Mayo Clinic, 40 women, 400 mg twice daily (NCT03564665), completed 2021, no results posted. Add-on to SSRIs (selective serotonin reuptake inhibitors, antidepressants such as sertraline), 90 patients (NCT04880460), completed 2021: serum magnesium rose versus placebo and correlated with lower depression scores (Sultana 2025).
  • Form comparisons: A systematic review found absorption is dose-dependent and organic forms may absorb better (Pardo 2021), but no head-to-head clinical-outcome trial compares bisglycinate with citrate; such trials could show the form adds nothing beyond magnesium itself.
  • Longevity outcomes: Supplemental magnesium showed no mortality association in cohorts (Bagheri 2021); no supplement trial has measured mortality or biological-age markers, so the longevity case remains untested.

Conclusion

Magnesium bisglycinate is magnesium bound to the amino acid glycine, sold as a well-tolerated way to raise magnesium intake. For health-focused adults, its value depends heavily on whether their magnesium intake or blood levels are low to begin with.

The most direct evidence for this form is modest. A single well-designed trial found a small improvement in self-reported insomnia, and smaller single trials suggest benefits for lung function in deficient patients with lung disease and for faster mood improvement alongside antidepressants. Better-known benefits of magnesium, such as slightly lower blood pressure, better blood sugar in diabetes and fewer migraines, come mostly from studies of cheaper forms of magnesium, so they apply to this form only by extension. Population studies tie magnesium from food, but not from supplements, to longer life. For night cramps in older adults, the better evidence shows little benefit.

The main risks are minor: this form caused no more digestive side effects than placebo capsules in its trials. Dangerous magnesium build-up is a real concern for people with poor kidney function, and magnesium reduces the absorption of several antibiotics, bone drugs, an antiviral drug, thyroid hormone and a nerve-pain drug unless doses are spaced apart.

The overall evidence base is small, recent and in places supplied or funded by supplement makers, and several of the most visible advocates sell magnesium products. The case for bisglycinate as a longevity tool rests on correcting low magnesium rather than on proven effects of the form itself.

Top - Benefits - Risks - Protocol